| Phthalimide conjugation as a strategy for in vivo target protein degradation GE Winter, DL Buckley, J Paulk, JM Roberts, A Souza, S Dhe-Paganon, ... Science 348 (6241), 1376-1381, 2015 | 1540 | 2015 |
| The dTAG system for immediate and target-specific protein degradation B Nabet, JM Roberts, DL Buckley, J Paulk, S Dastjerdi, A Yang, ... Nature chemical biology 14 (5), 431-441, 2018 | 765 | 2018 |
| Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer S Shu, CY Lin, HH He, RM Witwicki, DP Tabassum, JM Roberts, ... Nature 529 (7586), 413-417, 2016 | 605 | 2016 |
| BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment GE Winter, A Mayer, DL Buckley, MA Erb, JE Roderick, S Vittori, JM Reyes, ... Molecular cell 67 (1), 5-18. e19, 2017 | 403 | 2017 |
| Transcription control by the ENL YEATS domain in acute leukaemia MA Erb, TG Scott, BE Li, H Xie, J Paulk, HS Seo, A Souza, JM Roberts, ... Nature 543 (7644), 270-274, 2017 | 307 | 2017 |
| Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms M Kleppe, R Koche, L Zou, P van Galen, CE Hill, L Dong, S De Groote, ... Cancer cell 33 (1), 29-43. e7, 2018 | 282 | 2018 |
| Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors JH Kalin, M Wu, AV Gomez, Y Song, J Das, D Hayward, N Adejola, M Wu, ... Nature communications 9 (1), 53, 2018 | 205 | 2018 |
| Design and characterization of bivalent BET inhibitors M Tanaka, JM Roberts, HS Seo, A Souza, J Paulk, TG Scott, SL DeAngelo, ... Nature Chemical Biology 12 (12), 1089-1096, 2016 | 148 | 2016 |
| MELK is not necessary for the proliferation of basal-like breast cancer cells HT Huang, HS Seo, T Zhang, Y Wang, B Jiang, Q Li, DL Buckley, B Nabet, ... Elife 6, e26693, 2017 | 107 | 2017 |
| Genome-wide CRISPR screens reveal multitiered mechanisms through which mTORC1 senses mitochondrial dysfunction KJ Condon, JM Orozco, CH Adelmann, JB Spinelli, PW van der Helm, ... Proceedings of the National Academy of Sciences 118 (4), e2022120118, 2021 | 79 | 2021 |
| Structure-guided design and development of potent and selective dual bromodomain 4 (BRD4)/polo-like kinase 1 (PLK1) inhibitors S Liu, HO Yosief, L Dai, H Huang, G Dhawan, X Zhang, AM Muthengi, ... Journal of medicinal chemistry 61 (17), 7785-7795, 2018 | 57 | 2018 |
| Structural and atropisomeric factors governing the selectivity of pyrimido-benzodiazipinones as inhibitors of kinases and bromodomains J Wang, T Erazo, FM Ferguson, DL Buckley, N Gomez, ... ACS chemical biology 13 (9), 2438-2448, 2018 | 56 | 2018 |
| Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010–2014) M Tanaka, JM Roberts, J Qi, JE Bradner Pharmaceutical patent analyst 4 (4), 261-284, 2015 | 46 | 2015 |
| Pojamide: An HDAC3-selective ferrocene analogue with remarkably enhanced redox-triggered ferrocenium activity in cells CA Ocasio, S Sansook, R Jones, JM Roberts, TG Scott, N Tsoureas, ... Organometallics 36 (17), 3276-3283, 2017 | 31 | 2017 |
| A Bead‐Based Proximity Assay for BRD4 Ligand Discovery JM Roberts, JE Bradner Current protocols in chemical biology, 263-278, 2015 | 28 | 2015 |
| Zonated leucine sensing by Sestrin-mTORC1 in the liver controls the response to dietary leucine AL Cangelosi, AM Puszynska, JM Roberts, A Armani, TP Nguyen, ... Science 377 (6601), 47-56, 2022 | 26 | 2022 |
| Assessment of bromodomain target engagement by a series of BI2536 analogues with miniaturized BET‐BRET LW Koblan, DL Buckley, CJ Ott, ME Fitzgerald, SWJ Ember, JY Zhu, S Liu, ... ChemMedChem 11 (23), 2575-2581, 2016 | 22 | 2016 |
| Dynamics of the T ec‐family tyrosine kinase SH 3 domains JM Roberts, S Tarafdar, RE Joseph, AH Andreotti, TE Smithgall, ... Protein Science 25 (4), 852-864, 2016 | 14 | 2016 |
| Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses J Bradner, J Roberts, B Nabet, G Winter, AJ Phillips, T Heffernan, ... US Patent 11,046,954, 2021 | 13 | 2021 |
| Bivalent bromodomain inhibitors and uses thereof JE Bradner, J Qi, M Tanaka, JM Roberts US Patent 10,913,752, 2021 | 9 | 2021 |
Dennis BuckleyNIBR在 novartis.com 的电子邮件经过验证
